SCHEMBL680804

SCHEMBL680804

Cn1c(CN2CCOCC2)c(C(=O)Nc2ccc(Oc3cc4cn[nH]c4cc3-c3cccnc3)c(F)c2)c(=O)n1-c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.49
KDR P35968 5/20 0.49
IGF1R P08069 4/20 0.49
AXL P30530 3/20 0.49
FLT3 P36888 2/20 0.49
MERTK Q12866 2/20 0.49
TYRO3 Q06418 1/20 0.49
INSR P06213 1/20 0.46
MST1R Q04912 4/20 0.42
PLK4 O00444 1/20 0.42
NTRK1 P04629 1/20 0.42
RET P07949 1/20 0.42
DDR1 Q08345 1/20 0.42
CAMK4 Q16566 1/20 0.42
DDR2 Q16832 1/20 0.42
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12190648 0.88 MET (0.48) METKDRIGF1RAXLFLT3
SCHEMBL12190666 0.86 MET (0.64) METKDRIGF1RAXLFLT3
SCHEMBL680422 0.86 MET (0.46) METKDRIGF1RAXLFLT3
SCHEMBL680517 0.85 MET (0.55) METKDRIGF1RAXLFLT3
SCHEMBL679054 0.84 MET (0.61) METKDRIGF1RAXLFLT3
SCHEMBL680350 0.82 AXL (0.48) METKDRIGF1RAXLFLT3
SCHEMBL12190662 0.80 MET (0.62) METKDRIGF1RAXLFLT3
SCHEMBL12190699 0.78 MET (0.59) METKDRIGF1RAXLFLT3
SCHEMBL681088 0.78 MET (0.59) METKDRIGF1RAXLFLT3
SCHEMBL680500 0.77 MET (0.63) METKDRAXLFLT3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MET 1/4885KDR 180/4885IGF1R 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.